SG11201805990XA - Means and methods for staging, typing and treating a cancerous disease - Google Patents
Means and methods for staging, typing and treating a cancerous diseaseInfo
- Publication number
- SG11201805990XA SG11201805990XA SG11201805990XA SG11201805990XA SG11201805990XA SG 11201805990X A SG11201805990X A SG 11201805990XA SG 11201805990X A SG11201805990X A SG 11201805990XA SG 11201805990X A SG11201805990X A SG 11201805990XA SG 11201805990X A SG11201805990X A SG 11201805990XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- regensburg
- cancerous disease
- methods
- staging
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 230000000392 somatic effect Effects 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000004075 alteration Effects 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000001165 lymph node Anatomy 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16152883.1A EP3199641B1 (en) | 2016-01-27 | 2016-01-27 | Means and methods for staging, typing and treating a cancerous disease |
| PCT/EP2017/051789 WO2017129753A1 (en) | 2016-01-27 | 2017-01-27 | Means and methods for staging, typing and treating a cancerous disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805990XA true SG11201805990XA (en) | 2018-08-30 |
Family
ID=55310656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805990XA SG11201805990XA (en) | 2016-01-27 | 2017-01-27 | Means and methods for staging, typing and treating a cancerous disease |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11702701B2 (https=) |
| EP (2) | EP3199641B1 (https=) |
| JP (1) | JP2019508032A (https=) |
| KR (1) | KR20180102674A (https=) |
| CN (1) | CN108770360B (https=) |
| AU (1) | AU2017211976B2 (https=) |
| CA (1) | CA3012404A1 (https=) |
| ES (1) | ES2905208T3 (https=) |
| SG (1) | SG11201805990XA (https=) |
| WO (1) | WO2017129753A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1109938T3 (da) | 1998-09-18 | 2002-05-27 | Micromet Ag | DNA-amplificering af en enkelt celle |
| AU2002216009A1 (en) * | 2000-11-03 | 2002-05-15 | Michael Giesing | Clinical and functional validation of targets from disseminated cancer cells |
| ITRM20110149A1 (it) * | 2011-03-25 | 2012-09-26 | Massimo Zollo | Biomarcatore per la rilevazione di cellule tumorali circolanti e relativi metodi e kit di rilevazione. |
| US20140227692A1 (en) * | 2011-07-08 | 2014-08-14 | Deborah W. Neklason | Methods of detecting hereditary cancer predisposition |
| EP2788768A1 (en) * | 2011-12-10 | 2014-10-15 | Abbott Molecular Inc. | Materials and methods for diagnosis of malignant melanoma and prognosis of metastasis of malignant melanoma |
| WO2015023553A2 (en) * | 2013-08-13 | 2015-02-19 | Bionumerik Pharmaceuticals, Inc. | Contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of disease by administration of sulfur- containing, amino acid-specific small molecules |
| ES2730962T3 (es) | 2014-02-05 | 2019-11-13 | Fraunhofer Ges Forschung | Secuenciación libre de errores de ADN |
-
2016
- 2016-01-27 EP EP16152883.1A patent/EP3199641B1/en active Active
- 2016-01-27 ES ES16152883T patent/ES2905208T3/es active Active
-
2017
- 2017-01-27 KR KR1020187024606A patent/KR20180102674A/ko active Pending
- 2017-01-27 AU AU2017211976A patent/AU2017211976B2/en active Active
- 2017-01-27 CN CN201780008861.6A patent/CN108770360B/zh active Active
- 2017-01-27 SG SG11201805990XA patent/SG11201805990XA/en unknown
- 2017-01-27 EP EP17706412.8A patent/EP3408411A1/en not_active Withdrawn
- 2017-01-27 US US16/073,271 patent/US11702701B2/en active Active
- 2017-01-27 CA CA3012404A patent/CA3012404A1/en active Pending
- 2017-01-27 JP JP2018539138A patent/JP2019508032A/ja active Pending
- 2017-01-27 WO PCT/EP2017/051789 patent/WO2017129753A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN108770360A (zh) | 2018-11-06 |
| EP3408411A1 (en) | 2018-12-05 |
| WO2017129753A8 (en) | 2017-10-19 |
| ES2905208T3 (es) | 2022-04-07 |
| EP3199641B1 (en) | 2021-09-29 |
| KR20180102674A (ko) | 2018-09-17 |
| US20190062845A1 (en) | 2019-02-28 |
| JP2019508032A (ja) | 2019-03-28 |
| US11702701B2 (en) | 2023-07-18 |
| CN108770360B (zh) | 2022-06-14 |
| EP3199641A1 (en) | 2017-08-02 |
| AU2017211976B2 (en) | 2022-09-22 |
| AU2017211976A1 (en) | 2018-08-02 |
| CA3012404A1 (en) | 2017-08-03 |
| WO2017129753A1 (en) | 2017-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810611YA (en) | Coumarin compounds and their uses as fluorescent labels | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201810003UA (en) | Using programmable dna binding proteins to enhance targeted genome modification | |
| SG11201908787WA (en) | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap | |
| SG11201906553TA (en) | Methods and reagents for synthesising polynucleotide molecules | |
| SG11201809522WA (en) | Method of nucleic acid sequence determination | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201901834WA (en) | Micrornas as biomarkers for endometriosis | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201809530PA (en) | Method for recovery of phosphate | |
| SG11201810914VA (en) | Compositions and methods for diagnosing lung cancers using gene expression profiles | |
| SG11201810975UA (en) | Method for stabilizing proteins | |
| SG11201809413RA (en) | Detection of chromosome interaction relevant to breast cancer | |
| SG11201408434QA (en) | Targeted rna-seq methods and materials for the diagnosis of prostate cancer | |
| SG11201903428XA (en) | Pluripotent stem cell assay | |
| SG11201906313SA (en) | A polypeptide linker for preparing multispecific antibodies | |
| SG11201909882SA (en) | Targeted neoepitope vectors and methods therefor | |
| SG11201805497QA (en) | Mutated truncated von willebrand factor | |
| SG11201809996QA (en) | Ribonucleic acid (rna) interactions | |
| SG11201906778RA (en) | Improved methods for assessing risk of developing breast cancer |